Speech: John J. Castellani Remarks at Economist Pharma Summit 2013

Remarks
John Castellani
President & CEO
Pharmaceutical Research and Manufacturers of America


To:
The Economist Pharma Summit 2013
February 28, 2013
London, UK

Thank you for that kind introduction.

I’m here to talk about the future. But first allow me to address some of the criticism of the biopharmaceutical research industry I’ve heard today.

Member Companies

The biopharmaceutical industry invests billions to develop new medicines, treatments and cures that improve and extend our lives.

Learn more about our member companies and the exciting scientific discoveries they make.

If your company is interested in joining PhRMA,  click here.

Rotary International and PhRMA team up for “The World’s Biggest Commercial”

Evanston, Ill., USA  (Jan. 24, 2013) – Rotary International’s innovative campaign to develop the World’s Biggest Commercial to raise public awareness about polio eradication has struck a chord with the Pharmaceutical Research and Manufacturers of America (PhRMA).

To help spur participation in the commercial, the largest pharmaceutical trade group in the United States has donated $50,000 to Rotary’s PolioPlus program – enough to provide oral vaccine to protect more than 83,000 children against this paralyzing disease.

PhRMA Elects Four New Members to Board of Directors

Ian Read, President and Chief Executive Officer, Pfizer
Jerzy Gruhn, President, Novo Nordisk Inc.
Mark Iwicki, President and Chief Operating Officer, Sunovion Pharmaceuticals Inc.
Staffan Schüberg, President, Lundbeck Inc.

Washington, D.C. (December 21, 2010) –– The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced the election of four new members to its Board of Directors.

PhRMA Announces Two New Research Associate Members

Washington, DC (September 14, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that two companies – Ipsen Biopharmaceuticals and Onyx Pharmaceuticals – have joined the association as new research associate members. PhRMA’s Board of Directors recently approved the membership expansion.

PhRMA to Bestow New Research and Hope Award

Washington, D.C. (August 27, 2012)— For the first time in its history, the Pharmaceutical Research and Manufacturers of America (PhRMA) will bestow a Research and Hope Award to individuals from academia, the patient and caregiving community as well as the biopharmaceutical sector who have made significant contributions to the advancement of patient care and medical innovation in the U.S.  Each year, the award will honor advancements made in a selected therapeutic area, with this year’s award dedicated to Alzheimer’s disease.

Lilly’s John Lechleiter Becomes PhRMA Board Chairman

Boston, MA (April 13, 2012) — John C. Lechleiter, Ph.D., chairman, president and CEO of Eli Lilly and Company, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting. Also elected were Celgene Corporation President, CEO, and Chairman Robert J. Hugin as chairman-elect of the PhRMA Board of Directors, and Ian C. Read, president and CEO of Pfizer, Inc., as board treasurer.

Dr. Lechleiter succeeds Christopher Viehbacher, CEO of Sanofi, as PhRMA’s chairman.

Rod Hunter Joins PhRMA as Senior VP, International Advocacy

Washington, D.C. (May 9, 2011) — The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced that Rod Hunter has been named Senior Vice President of International Advocacy, effective June 10, 2011. Hunter will report to Executive Vice President of Advocacy Chip Davis.

In his new role, Hunter will be responsible for leading and overseeing PhRMA’s international advocacy functions. He comes to PhRMA from IBM, where he served as Vice President, Governmental Programs, Europe.

Christopher Viehbacher Continues as PhRMA Board Chair; John Lechleiter, Robert Hugin Assume New Posts

Washington, D.C. (April 15, 2011) — Christopher Viehbacher, Chief Executive Officer of sanofi-aventis, resumed his role as board chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association’s annual meeting in Jersey City, New Jersey. John C. Lechleiter, Ph.D., Chairman, President and Chief Executive Officer of Eli Lilly and Company, was elected as chairman-elect of the PhRMA Board of Directors, and Robert J. Hugin, President and Chief Executive Officer of Celgene Corporation, was elected PhRMA’s board treasurer.

PhRMA Statement on State of the Union Address

Washington, D.C. (January 25, 2011) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani released the following statement in response to the President's State of the Union address:

“We commend the President for offering an ambitious agenda that focuses on bolstering the economy, job growth and strengthening our education system to ensure that we attract and retain the world’s best and brightest talent.

Pages

Subscribe to RSS - About